24 de agosto de 2019
  • Viernes, 23 de Agosto
  • Jueves, 22 de Agosto
  • 10 de septiembre de 2018

    flutiform® k-haler®, a Novel Treatment for Adolescents and Adults With Asthma, Now Available in Europe (2)

    8. Kappeler D, et al. Lung deposition of fluticasone propionate/formoterol administered via a breath-triggered inhaler. Resp Med 138 (2018) 107-114 

    9. Bell D, L Mansfield, M Lomax. A Randomized, Crossover Trial Evaluating Patient Handling, Preference, and Ease of Use of the Fluticasone Propionate/Formoterol Breath-Triggered Inhaler. J Aerosol Med Pulm Drug Deliv 2017a;30(6):425-34. 

    10. European Respiratory Society. The European Lung White Book. 2013 

    11. Price D, et al. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. npj Primary Care Respiratory Medicine 2014. doi:10.1038/npjpcrm.2014.9 

    12. Raimundo K, et al. Relationships between asthma control, productivity and health outcomes in a US survey. European Resp J 2016 48: PA4219; DOI: 10.1183/13993003.congress-2016.PA4219

    Photo: https://mma.prnewswire.com/media/685081/Mundipharma_Logo.jpg

    CONTACT: Tiffany Fretwell, Communications Lead, Mundipharma InternationalLtd, Tiffany.Fretwell@mundipharma.com, +44-(0)-7773-199-422; Nicola Lilley,Account Director, Havas SO, Nicola@sowhatglobal.com, +44-(0)-7983-128-712